Q3 FY2026 · ended Sep 30, 2026 · Revenue $41.96M, +12.5% YoY · Filed Nov 4, 2026
Neuronetics, Inc. (STIM) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $42.0 million and a net loss of $1.7 million. Free cash flow was $768,000. As of Sep 30, 2026 it held $22.1 million in cash and investments and $87.7 million in total debt.
Revenue
$41.96M
+12.5% vs year-ago quarter
Net income
$-1.69M
+81.3% vs year-ago quarter
Operating cash flow
$1.24M
+257.7% vs year-ago quarter
Free cash flow
$768,000
+185.4% vs year-ago quarter
EPS
$-0.02
+84.6% vs year-ago quarter
Dividend per share
None
Shares outstanding
77.73M
+13.5% vs year-ago quarter
Net cash
$-65.62M
Q3 FY2026
Operating margin
-9.4%
TTM
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- STIM (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Malvern, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1227636
- Former names
- Neuronetics, Inc. (until Nov 4, 2026); NEURONETICS INC (until Aug 16, 2006)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $42.0M | $41.6M | $34.5M | $41.8M | $37.3M |
| Operating income | $541,000 | -$1.5M | -$9.0M | -$5.0M | -$7.3M |
| Net income | -$1.7M | -$3.4M | -$10.8M | -$7.2M | -$9.0M |
| Diluted EPS | -$0.02 | -$0.05 | -$0.16 | -$0.10 | -$0.13 |
| Operating cash flow | $1.2M | -$1.0M | -$9.4M | $882,000 | -$785,000 |
| Free cash flow | $768,000 | -$1.4M | -$9.6M | $666,000 | -$899,000 |
| Total assets | $132.0M | $131.5M | $125.4M | $141.6M | $145.5M |
| Total liabilities | $109.6M | $109.9M | $108.4M | $115.3M | $114.1M |
| Stockholders' equity | $18.7M | $17.9M | $13.3M | $22.4M | $27.4M |
| Cash and investments | $22.1M | $19.2M | $13.2M | $28.1M | $28.0M |
| Total debt | $87.7M | $86.5M | $85.4M | $90.3M | $90.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 17, 2026 | Aug 11, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jul 20, 2026 | Jul 9, 2026 |
All 719 Neuronetics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.